Mazor Robotics Ltd. , an Israel-based developer of robotic technology and products, recently presented data from two clinical studies at a leading Spine Conference. The data demonstrated major clinical benefits of its surgical guidance technological platform.
The studies confirmed an improvement in patient outcomes when surgeons utilized Mazor Robotic’s Renaissance-guidance system. The system guides the surgeon’s instruments to ensure highest levels of accuracy during minimally-invasive surgery (MIS).
The study confirms that usage of robotic guidance in MIS approach can significantly reduce the surgical complications and revision rates compared to both freehand MIS as well as open cases. Notably, these studies corroborate the clinical and economic value proposition of Renaissance system by delivering positive results which meet the surgeon’s expectation.
As per a report by StarTribune, more than 16,000 successful spinal surgeries have been performed worldwide with the Renaissance system, which is a major positive for Mazor Robotics. We believe that the company will continue to win contracts for the same that will propel significant top-line growth.
New Platform for Spinal Surgeries
Meanwhile, Mazor Robotics recently introduced Mazor X, a revolutionary platform for spine surgeries using highly automated robotic technologies. The company is slated to commercially launch the FDA-cleared Mazor X by Oct 2016.
The company also agreed to a commercial co-promotion and co-development deal with Medtronic (MDT - Free Report) , under which the latter has already added 15 Mazor X systems.
Our Take
Mazor Robotics has managed to gain considerable traction in new metropolitan markets and in academic centers within a short span of time.
Internationally, Mazor Robotics continues to work with its distribution partners to expand into the market. On the regulatory front, the company continues to make progress and move closer to approvals in key markets like Japan and South Korea.
Zacks Rank & Key Picks
Mazor Robotics has a Zacks Rank #2 (Buy).
Other favorably ranked stocks in the medical sector are Masimo Corporation (MASI - Free Report) and Mesa Laboratories Inc. (MLAB - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Mazor Robotics Ltd. , an Israel-based developer of robotic technology and products, recently presented data from two clinical studies at a leading Spine Conference. The data demonstrated major clinical benefits of its surgical guidance technological platform.
The studies confirmed an improvement in patient outcomes when surgeons utilized Mazor Robotic’s Renaissance-guidance system. The system guides the surgeon’s instruments to ensure highest levels of accuracy during minimally-invasive surgery (MIS).
The study confirms that usage of robotic guidance in MIS approach can significantly reduce the surgical complications and revision rates compared to both freehand MIS as well as open cases. Notably, these studies corroborate the clinical and economic value proposition of Renaissance system by delivering positive results which meet the surgeon’s expectation.
As per a report by StarTribune, more than 16,000 successful spinal surgeries have been performed worldwide with the Renaissance system, which is a major positive for Mazor Robotics. We believe that the company will continue to win contracts for the same that will propel significant top-line growth.
New Platform for Spinal Surgeries
Meanwhile, Mazor Robotics recently introduced Mazor X, a revolutionary platform for spine surgeries using highly automated robotic technologies. The company is slated to commercially launch the FDA-cleared Mazor X by Oct 2016.
The company also agreed to a commercial co-promotion and co-development deal with Medtronic (MDT - Free Report) , under which the latter has already added 15 Mazor X systems.
Our Take
Mazor Robotics has managed to gain considerable traction in new metropolitan markets and in academic centers within a short span of time.
Internationally, Mazor Robotics continues to work with its distribution partners to expand into the market. On the regulatory front, the company continues to make progress and move closer to approvals in key markets like Japan and South Korea.
Zacks Rank & Key Picks
Mazor Robotics has a Zacks Rank #2 (Buy).
Other favorably ranked stocks in the medical sector are Masimo Corporation (MASI - Free Report) and Mesa Laboratories Inc. (MLAB - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MDT - FREE
Get the latest research report on MASI - FREE
Get the latest research report on MLAB - FREE